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Introduction
If genius is the ability to reduce the complicated to the simple, 
then the study of p53 makes fools of us all. Beyond the indis-
putable importance of p53 as a tumor suppressor, an increas-
ing and sometimes bewildering number of new roles for p53 
have recently been reported, including the ability to regulate 
metabolism, fecundity, and various aspects of differentia-
tion and development. We are beginning to develop an inti-
mate understanding of at least some of p53’s functions and 
the mechanisms by which p53 is regulated. It is very clear, 
for example, that p53 is a transcription factor and regulates 
the expression of an array of different genes (encoding both 
proteins and microRNAs) that then mediate the p53 response. 
However, despite this intensive effort, there is still much to 
learn, and p53 remains a highly dynamic and rapidly expand-
ing area of study. It is impossible to cover all aspects of p53-
associated biology in one review, and so we have reluctantly 
passed over many fascinating topics that include the mecha-
nisms that signal to p53; the relationships between p53 and 
its family members p63 and p73; the regulation of p53 expres-
sion, turnover, and localization; the effects of polymorphisms 
in components of the p53 pathways; the expression of differ-
ent p53 isoforms; and the consequences of p53 mutations that 
occur during cancer development. Instead, we have chosen a 
few emerging themes to give a flavor of some recent advances 
in the p53 world.
p53 and Tumor Suppression: All that Is Good
The ability of p53 to efficiently inhibit cell proliferation—by 
both blocking cell cycle progression and promoting apoptotic 
cell death—provides a clear mechanism to stem tumor cell 
growth and so inhibit cancer development. Activation of p53 
is driven by a wide variety of stress signals that a cell might 
encounter during malignant progression—genotoxic dam-
age, oncogene activation, loss of normal cell contacts, and 
hypoxia to name but a few—leading to a model in which the 
growth inhibitory functions of p53 are normally held dormant, 
to be unleashed only in nascent cancer cells. But the situa-
tion is much more complex. We now understand that some 
p53 functions do not require activation by acute stress and 
that p53 can promote what appear to be entirely contradic-
tory outcomes, although each of them may have a critical role 
to play in tumor suppression.
Death: The Final Frontier?
The concept that p53 can kill cancer cells is made even more 
pleasing by the idea that p53 might selectively induce apop-
tosis in developing tumor cells, while driving only a reversible 
cell-cycle arrest in their normal counterparts. As we will see, 
this is a massive oversimplification of the complex and het-
erogeneous responses to p53 activation, where some types 
of normal cells die while some types of tumor cells survive. 
Nevertheless, the possibility that the response to p53 activa-
tion can be modulated and that the therapeutic activation of 
p53 might be manipulated to promote death more efficiently 
in tumor cells than in normal cells is very attractive. Numer-
ous studies have sought to reveal the molecular mechanisms 
that underlie the control of the response to p53 activation. But 
before we discuss them, let us take a step back and reconsider 
the real contribution of p53-induced apoptosis to tumor sup-
pression.
Many of our models for p53 function suppose that induc-
tion of programmed cell death is the key mechanism by which 
p53 eliminates cancer cells. Indeed, mice that express a p53 
mutant protein lacking the ability to induce cell cycle arrest 
but retaining apoptosis-inducing functions are still efficiently 
protected from spontaneous tumor development (Toledo et 
al., 2006). However, a growing body of evidence indicates that 
other functions of p53 may be equally important to prevent or 
stall cancer development. A clear hint that apoptosis is not 
the only weapon in p53’s tumor suppressive arsenal comes 
from the identification of PUMA (p53-upregulated modulator of 
apoptosis) as a key mediator of p53’s apoptotic activity. PUMA 
is a BH3 (Bcl-2 homology domain 3)-only protein that induces 
apoptosis through the mitochondrial pathway. The study of 
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PUMA null mice showed that the induction of PUMA by p53 is 
necessary for the apoptotic response to p53 activation in many 
tissues (Yu and Zhang, 2003). However, PUMA null mice are not 
prone to developing cancer (Michalak et al., 2008), although 
subsequent studies have shown that the loss of PUMA can 
promote tumorigenesis that is driven by the Myc oncogene 
(Garrison et al., 2008; Hemann et al., 2004). It therefore seems 
clear that p53 can retain tumor suppressive functions even 
in the absence of a robust apoptotic response. The analysis 
of an unusual mutant p53 protein led to similar conclusions. 
Whereas most cancer-associated p53 mutations destroy all 
tested activities of p53, a few tumors harbor mutations in p53 
that allow the protein to retain its cell cycle arrest function but 
selectively lose its ability to induce apoptosis (Rowan et al., 
1996). The generation of mice expressing one such mutant (a 
single amino acid substitution of proline for arginine at residue 
172 in the mouse—the equivalent of residue 175 in the human 
protein) revealed a very interesting phenotype. Despite being 
completely deficient in p53-driven apoptosis, these mice are 
still reasonably well protected from tumor development (Liu et 
al., 2004). Clearly, other functions retained by this mutant p53 
protein can, at least partially, impede tumor development.
Not Dying, but Stopping
So what else might p53 be doing to prevent cancer develop-
ment? There are several interesting options, including a num-
ber of different antiangiogenic activities of p53 that could limit 
tumor progression (Teodoro et al., 2007). But maybe the most 
obvious candidate for another tumor suppressor activity of p53 
is the ability to inhibit cell proliferation and growth (Figure 1). 
p53 can effectively block cell cycle progression by activating 
the transcription of the cyclin-dependent kinase inhibitor p21, 
although several other p53-target genes such as 14-3-3 sigma 
and GADD45 also contribute to this response (El-Deiry, 1998). 
The induction of p21 expression is extremely sensitive to even 
low levels of p53 protein, leading to the idea that a temporary 
G1 block, as induced by mild damage or stress, allows cells to 
survive safely until the damage has been resolved or the stress 
removed (we will come back to this idea). However, a transient cell 
cycle arrest might be risky, if a cell with oncogenic potential that 
cannot be repaired is allowed to endure 
and ultimately resume proliferation. So 
how can cancer cells be permanently 
restrained, if not through elimination by 
apoptotic cell death? The answer seems 
to lie in the activation of senescence—
an irreversible cell cycle arrest. A slew of 
fascinating studies have highlighted the 
importance of senescence in the inhibi-
tion of tumor progression and have identified a key role for p53 
in this response. Several of these studies show that a pivotal 
point in this pathway is the induction of DNA damage, by onco-
gene activation or in response to telomere dysfunction, which in 
turn leads to the activation of p53 (Deng et al., 2008; Halazonetis 
et al., 2008). It would appear that precancerous lesions, which 
we probably all carry in abundance, are largely held back from 
malignant progression by p53-induced senescence. Small sur-
prise, then, that the loss of p53 has such a dramatic effect in 
allowing cancer to develop. Furthermore, senescence remains 
an important response to p53 activation, even in established 
tumors. In mouse models, reactivation of p53 proves to be a 
potently effective therapy for cancer, resulting in the regression 
of many different tumor types (Martins et al., 2006; Ventura et al., 
2007; Xue et al., 2007). Most interesting is the type of response 
to p53 activitation, which in carcinomas and sarcomas triggers 
senescence rather than apoptosis. Although tissue culture stud-
ies would suggest that senescence is a cytostatic response that 
should promote stabilization of the disease rather than induce 
its regression, encouraging results from in vivo studies indicate 
that the subsequent engagement of the immune system can 
result in tumor clearance (Xue et al., 2007).
As with other p53 responses, senescence is likely to result 
from changes in the expression of a number of proteins such 
as the plasminogen activator inhibitor 1 (PAI-1) (Kortlever et 
al., 2006; Leal et al., 2008). Intriguingly, one of the key media-
tors of p53-induced senescence is p21 (Brown et al., 1997), 
and tumor suppression by the apoptosis-defective p53 R172P 
mutant is accompanied by the activation of p21 and senes-
cence (Cosme-Blanco et al., 2007; Van Nguyen et al., 2007). 
Furthermore, introduction of this p53 mutant into p21 null mice 
results in the complete loss of the cell cycle arrest response 
and enhanced tumorigenicity (Barboza et al., 2006). Taken 
together, these results suggest that p53-dependent activation 
of p21 is an important axis in senescence-dependent tumor 
suppression. However, a recent study showed that although 
p21 plays an important role in mediating the p53-dependent 
cellular response to stress, lack of p21 does not strongly pro-
mote tumor development (Choudhury et al., 2007). In some 
Figure 1. p53 Responses in Mediating 
Tumor Suppression
The control of cell survival, proliferation, and death 
by p53 is mediated by the regulation of expres-
sion of p53 target genes (some examples shown in 
blue) in the nucleus and transcriptionally indepen-
dent cytoplasmic functions of p53. Most of these 
p53 responses have the potential to contribute to 
tumor suppression.
Cell 137, May 1, 2009 ©2009 Elsevier Inc. 415
ways, this result parallels the failure of PUMA null mice to 
spontaneously develop cancer, despite a clear defect in p53-
dependent apoptosis. Perhaps the senescent and apoptotic 
responses act as insurance for each other (a sort of tumor 
suppressive belt and braces) with the predominant response 
depending on cell type and context. An analysis of the tumor 
spectrum of mice lacking both p21 and PUMA would be most 
interesting.
Choosing Life or Choosing Death
The tumor suppressive effects of p53-dependent induction 
of either senescence or cell death are easy to understand, as 
both can emphatically prevent further replication of the incipi-
ent cancer cell. In a multicellular organism, this seems to be the 
sensible choice—better to lose a few rogue cells to death or 
senescence rather than risk retaining one cell that might prove 
fatal. Despite the inherent logic of this argument, the cellular 
response to p53 is not so straightforward. In addition to elimi-
nating damaged cells, p53 can also contribute to cell survival 
through a surprisingly large number of mechanisms (Figure 1). 
Numerous p53 target proteins function to inhibit apoptosis, 
including p21, decoy death receptors such as DcR1 and DcR2, 
the transcription factor SLUG (which represses the expression 
of PUMA), and several activators of the AKT/PKB (protein kinase 
B) survival pathways (Janicke et al., 2008). Another group of 
p53-inducible genes have recently also been shown to act as 
antioxidants by decreasing the levels of intracellular reactive 
oxygen species (Liu et al., 2008; Sablina et al., 2005). Although 
this function for p53 would help inhibit tumor progression by 
protecting cells against DNA damage and genome instability, 
downregulation of reactive oxygen species through these p53-
dependent mechanisms can also result in decreased suscep-
tibility to apoptosis (Bensaad et al., 2006).
So why would p53 contribute to cell survival when promoting 
death seems to be the safest option? The implication is that the 
wholesale elimination of every cell that is exposed to some level 
of stress, no matter how mild, is not always the most desirable 
response. It is possible that survival promotes senescence, 
which is simply another way to permanently remove a prob-
lematic cell. Indeed, it may be telling that p21, a key mediator 
of p53-induced senescence, also plays a role in cell survival. 
However, it also seems likely that under some conditions, this 
activity of p53 really does protect cells, allowing them to rejoin 
the normal population after the resolution of any damage. p53 
engages an entire suite of responses that directly contribute to 
DNA repair (Gatz and Wiesmuller, 2006), so it seems only logi-
cal to assume that under some circumstances these activities 
of p53 will be harnessed for use—and there seems little point 
in repairing a cell that is doomed to die or senesce.
This brings us to the interesting question of what determines 
the outcome of p53 activation. Whether or not an apoptotic 
response is elicited is strongly dependent on the type of tis-
sue, the nature of the stress signal, and the cell’s environment. 
But there is also some evidence to suggest that the deci-
sion between life and death can be determined by the extent 
of damage or the duration of stress (Figure 2). In this model, 
low levels of transient stress associated with repairable dam-
age elicit the survival response (where p53 acts as a protec-
tor), whereas high levels of sustained stress accompanied by 
irreparable damage lead to cell death or senescence (where 
p53 acts as a killer) (Bensaad and Vousden, 2007). Despite the 
clear difference in outcomes, both of these responses to p53 
could contribute to tumor suppression, either by preventing the 
accumulation of oncogenic lesions or by eradicating damaged 
cells through cell death or senescence. This model also sug-
gests that there are activities of p53 (as a protector) that might 
be extremely dangerous to sustain under conditions where 
repair or recovery is not possible. We will revisit this point later 
in the discussion.
Controlling the Engine
Oncogenic changes that promote cancer cell proliferation and 
survival are often accompanied by alterations in cell metabo-
lism that also play a vital role in supporting tumor development 
Figure 2. Dual Mechanisms of p53 Function 
in Tumor Suppression and Aging
p53 can help to promote the repair and survival of 
damaged cells, or it can promote the permanent 
removal of damaged cells though death or senes-
cence. The ultimate result of p53 activation de-
pends on many variables, including the extent of 
the stress or damage. In this model, basal p53 ac-
tivity or that induced by low-stress elicits the pro-
tector responses that support cell survival, control 
glycolysis, and promote the repair of genotoxic 
damage. Sustained stress or irreparable damage, 
on the other hand, induces the killer functions of 
p53 to activate cell death or senescence. Notably, 
the protector functions of p53 could contribute to 
tumor development if not properly regulated (red, 
dashed arrow). Some of p53’s protector functions 
may also help to enhance longevity, whereas the 
consequences of p53’s killer functions can pro-
mote aging.
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(DeBerardinis et al., 2008). This is a complex subject, but in 
essence the reprogramming of metabolic pathways provides 
cancer cells with numerous benefits, including the ability to 
survive under adverse conditions (such as low or variable oxy-
gen availability), the ability to mobilize anabolic pathways that 
generate the macromolecules necessary for growth, and the 
ability to limit oxidative damage (DeBerardinis et al., 2008). 
Indeed, the dependence of cancers on metabolic transforma-
tion is highlighted by mouse models of cancer in which inter-
fering with these altered metabolic programs profoundly limits 
tumor cell growth (Bonnet et al., 2007; Christofk et al., 2008; 
Fantin et al., 2006). A role for p53 in responding to and regulat-
ing metabolic changes is therefore an exciting and burgeoning 
area of study.
So how does p53 contribute to the regulation of metabolism, 
and how might this help it to function as a tumor suppressor? 
Not surprisingly, p53 can be activated by metabolic adver-
sity (such as starvation)—a response that can be mediated 
through the action of AMP-activated protein kinase (AMPK), 
a key component of the cell’s response to bioenergetic stress 
(Jones et al., 2005). p53 then promotes a program of gene 
expression (including the induction of AMPK expression) 
to negatively regulate the kinase mTOR (mammalian target 
of rapamycin), a central node in the control of protein syn-
thesis (Budanov and Karin, 2008; Feng et al., 2007a) (Figure 
1). This response to p53 helps to ensure the coordination of 
cell growth and cell proliferation, which is also regulated by 
p53. A role for p53 in the response to starvation and meta-
bolic stress is also reflected in the ability of p53 to regulate 
autophagy, a membrane trafficking-mediated “self-eating” 
process that results in lysosomal digestion of cellular com-
ponents. Autophagy promotes short-term cellular survival 
under starvation conditions and also helps to eliminate dam-
aged proteins and organelles. The ability of p53 to promote 
autophagy through the induction of lysosomal proteins such 
as DRAM (damage-regulated autophagy modulator) (Crighton 
et al., 2006) or through negative regulation of mTOR signaling 
is certainly consistent with an observed role for autophagy in 
tumor suppression (Matthew et al., 2007) (Figure 1). But the 
relationship between p53 and autophagy remains unclear—
indeed basal levels of cytoplasmic p53 have been shown to 
inhibit autophagy, also by regulating mTOR activity (Tasde-
mir et al., 2008). Similarly complicated are the consequences 
of autophagy for tumor suppression, as p53-associated 
autophagy has been reported to both contribute to apoptosis 
(Crighton et al., 2006) and help tumor cell survival (Amaravadi 
et al., 2007). How these opposing responses to p53-induced 
autophagy are coordinated remains to be determined.
In addition to regulating growth through modulating mTOR 
signaling, p53 may have even more intricate roles in the reg-
ulation of metabolic pathways (Jones and Thompson, 2009). 
These recently uncovered functions include modulating glu-
cose uptake (Kawauchi et al., 2008), dampening glycolysis 
(Bensaad et al., 2006; Kondoh et al., 2005), and enhancing 
mitochondrial respiration (Ma et al., 2007). Intriguingly, some 
of these effects of p53 could help to curb the acquisition of 
enhanced aerobic glycolysis (the Warburg effect), one of the 
most common metabolic changes associated with oncogenic 
transformation. Thus, they may provide yet another route by 
which p53 can restrain tumor development.
p53 and Tumor Promotion: Crossing to the Dark Side
Our recent appreciation of p53’s role in regulating glycolysis, 
oxidative stress, and cell survival leads us to a growing tangle of 
complexity within the p53 pathway, where p53 can be involved 
in disparate and even contradictory responses. These func-
tions of p53 highlight an interesting paradox touched on ear-
lier: if some activities of p53 that normally contribute to tumor 
suppression are not properly regulated, they might “switch 
sides” to help promote cancer development (Figure 2). Obvi-
ous examples include the prosurvival functions of p53, which 
might protect cells undergoing repair following mild stress but 
would be extremely counterproductive if maintained in irrep-
arably damaged cells. Similarly, the ability of p53 to impede 
glycolysis can help control oncogenic transformation, but 
the consequent promotion of alternative metabolic pathways 
(such as the pentose phosphate pathway) might also drive the 
anabolism necessary for tumor cell growth (DeBerardinis et al., 
2008). Nontranscriptional functions of p53 such as its role in 
inhibiting autophagy could also contribute to tumor develop-
ment under some circumstances. Intriguingly, this particular 
function of wild-type p53 is retained by cancer-associated 
Figure 3. p53 Contributes to Multiple 
 Normal Processes and Disease Pathologies
In addition to its well-known role as a tumor sup-
pressor, p53 also regulates other cellular (right) 
and developmental processes (left). These include 
processes that result in positive outcomes (red 
arrow) and those that result in diseases or other 
unfavorable outcomes (black arrow). Examples of 
p53 target genes (blue) that are regulated by p53 
to produce the indicated cellular outcomes of p53 
induction are shown. Note that, in many cases, nu-
merous targets have been identified to mediate a 
specific outcome, even though only one example 
target gene is shown here.
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mutant p53 proteins (Morselli et al., 2008), although whether 
this activity helps malignant progression is not yet known. It 
would appear that the tight restriction of some p53 responses 
may be necessary to prevent one of our principal tumor sup-
pressors from turning from friend to foe.
p53 in Other Pathologies
Although the ability of p53 to drive processes such as cell 
death is clearly beneficial in the context of limiting tumor devel-
opment, engaging these p53-mediated responses under all 
stress conditions may not necessarily be advantageous. For 
instance, the DNA-damage-induced p53 response is largely 
responsible for radiation or chemotherapy-induced sickness. 
Although this has often been viewed as an unfortunate but 
necessary side effect of activating the important genome pro-
tection functions of p53, more recent work has shown, rather 
surprisingly, that this initial p53 response is not required for 
tumor suppression (Christophorou et al., 2006; Efeyan et al., 
2006). Rather, it seems that the ability of p53 to sense and 
respond to oncogene activation is the key to preventing can-
cer, suggesting that transient inhibition of p53 might be use-
ful in protecting normal tissue from the short-term negative 
effects of cancer therapies (Berns, 2006). Beyond cancer, the 
fact that p53 responds to a myriad different types of stress 
without being able to distinguish when this is helpful and when 
not results in its involvement in a number of negative effects 
(Figure 3). For example, the induction of p53-driven apoptosis 
in response to hypoxia is clearly an asset when the hypoxia 
is caused by a lack of blood supply in a rapidly growing 
tumor. However, this response is much less desirable when 
the hypoxia is due to ischemia following stroke or myocardial 
infarction. Indeed, inhibition of p53 seems to be extremely 
beneficial during the early stages of ischemia or during sub-
sequent reperfusion injury (Liu et al., 2006). The activation of 
p53 by ribosomal stress has been linked to tumor suppres-
sion, with abnormalities in the expression of several ribosomal 
proteins resulting in an increased tumor susceptibility in dis-
orders such as Diamond Blackfan Anemia, possibly reflect-
ing a failure to properly activate p53 (Montanaro et al., 2008). 
On the other hand, perturbation of ribosome biosynthesis 
by mutations in TCOF1 (Treacher Collins-Franceschetti syn-
drome 1) can cause constitutive activation of p53 (Jones et al., 
2008) and result in the congenital disorder known as Treacher 
Collins syndrome. Similarly, p53 appears to contribute to the 
pathology of various neurodegenerative diseases. Activation 
of p53 by mutant forms of huntingtin (which are responsible 
for Huntington’s disease) partially mediates the neurode-
generation and neurobehavioral abnormalities observed in 
mouse models (Bae et al., 2005). In turn, p53 further induces 
the expression of huntingtin (Feng et al., 2006), an effect that 
might further exacerbate the progress of the disease. In ani-
mal models of Parkinson’s disease, the loss of DJ-1 expres-
sion (a gene mutated in early onset Parkinson’s disease in 
man) leads to the activation of p53 and the death of dopamin-
ergic neurons (Bretaud et al., 2007). p53 has also been impli-
cated as a mediator of neuronal death in Alzheimer’s disease 
(Culmsee and Landshamer, 2006), although recent studies 
suggest that expression of amyloid-beta peptides associated 
with Alzheimer’s may induce a conformational shift in the p53 
protein (Lanni et al., 2007). This effect might provide a use-
ful additional marker for the diagnosis of Alzheimer’s and also 
presents the intriguing possibility that the unfolding of p53 into 
a “mutant” conformation may contribute to the development 
of the disease. While these findings highlight the potentially 
detrimental effects of p53 activity in the nervous system, the 
ability of p53 to promote neural outgrowth and axon regenera-
tion suggest that it can also have a more positive contribution 
to neuronal regeneration after central or peripheral nervous 
system injuries (Di Giovanni et al., 2006).
Everyday p53 Functions: No Stress, No Worries?
One of the most interesting shifts in our thinking about p53 
is the realization that its remit may be far broader than sim-
ply to promote a tumor suppressive response to acute stress. 
Indeed, the ability to prevent cancer has been suggested to 
be an “evolutionarily late” cooption of p53 activities that had 
initially evolved to protect the germline and monitor develop-
ment (Aranda-Anzaldo and Dent, 2007; Vousden and Lane, 
2007) (Figure 3). These primordial functions of p53 as a guard-
ian of the germline appear in lower organisms (such as flies 
and worms) that have no clear need for cancer suppression 
(Derry et al., 2001; Sutcliffe and Brehm, 2004) and are also 
reflected in its ability to protect mouse embryonic stem cells 
from DNA damage by inducing their differentiation (Lin et al., 
2005). A role for p53 in differentiation and development is also 
observed in the frog Xenopus laevis, where p53 engages in 
complex interactions with the Smad transcriptional regulators 
to direct embryonic germ layer specification (Piccolo, 2008). 
p53 even makes a subtle but important contribution to sev-
eral aspects of normal growth and development in mice, where 
the p53 family members p63 and p73 shoulder the bulk of the 
developmental functions (Aranda-Anzaldo and Dent, 2007; 
Vousden and Lane, 2007).
It is now becoming apparent that the manifestations of some 
of p53’s functions in diverse aspects of health and disease 
(Figure 3) do not require acute stress. Rather, these p53 func-
tions depend on basal levels of p53 or the activation of p53 
by low levels of constitutive stress. One possible function for 
basal p53 activity is in the control of stem cell renewal. Even in 
the absence of obvious stress, p53 can limit the self-renewal 
of adult neural stem cells (Meletis et al., 2006) and regulate 
quiescence in hematopoietic stem cells (Liu et al., 2009). p53 
also represses the expression of CD44, cell surface proteins 
involved in regulating many aspects of cell migration and sur-
vival (Godar et al., 2008). This may represent another contribu-
tion to tumor suppression, but the observation that basal levels 
of p53 can also control CD44 suggests a mechanism by which 
p53 could be involved in regulating normal functions of CD44, 
such as epithelial development or stem cell renewal. In other 
studies, p53 has been shown to contribute to fecundity in mice 
by directly regulating the expression of leukemia inhibitory fac-
tor (LIF), a protein required for blastocyte implantation (Hu et 
al., 2007). Most interestingly, polymorphisms known to affect 
p53 activity are associated with implantation failures in women 
(Kay et al., 2006), hinting at the conservation of this function of 
p53 in humans.
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The ability of basal p53 activity to modulate metabolism 
may also have some interesting consequences beyond the 
control of cancer development. For example, the ability of p53 
to promote aerobic respiration appears to be critical in mice 
to maintain endurance during exercise (Matoba et al., 2006). 
But maybe the most intriguing additional role for p53 is in the 
regulation of longevity and aging (Figure 2). In lower organ-
isms such as worms and flies, the loss of p53 can be asso-
ciated with increased longevity (Arum and Johnson, 2007; 
Bauer et al., 2005). Initial studies suggested that p53 could 
also drive premature aging in mammalian systems, although 
there is some indication that this effect may be the conse-
quence of inappropriate, unregulated p53 activity—possibly 
reflecting enhanced oxidative stress (Matheu et al., 2008). By 
contrast, our more recent understanding of the antioxidant 
functions of basal (uninduced) levels of p53 and the ability of 
p53 to negatively regulate the IGF-1/mTOR growth regulation 
pathways suggest an alternative possibility: that p53 activity 
enhances longevity. Indeed, mice engineered to express addi-
tional copies of normally regulated p53 showed resistance to 
cancer without any accelerated aging (Matheu et al., 2007). In 
fact, in combination with increased copies of the tumor sup-
pressor Arf, the enhanced p53 allele even enhances longevity 
in mice (Matheu et al., 2007). Thus, just as p53 can function 
as both protector and killer in its role as a tumor suppressor, it 
may also both promote and prevent aging (Figure 2). Interest-
ingly, p53 function has been shown to decline with age (Feng 
et al., 2007b). This could contribute not only to the increased 
incidence of cancer with increased age but also possibly to 
the process of aging itself. Can p53 activity be somehow har-
nessed to allow us to both avoid cancer and enjoy increased 
longevity? This may be a dream, but it is certainly a question 
worth examining.
The Nuts and Bolts of p53 Regulation
As outlined above, the consequences of p53 activation can 
be dramatically different depending on numerous factors and 
contexts. Differences in stimuli, cellular milieu, or external 
environment can result in different p53-dependent outcomes. 
How are such decisions in cellular outcomes made? Stud-
ies performed in past 5 years have provided deeper insights 
into this question. Myriad transcriptional targets mediate 
the diverse outcomes of p53 activation (Figure 3). Although 
most p53 targets are only induced by types of stress that 
lead to increased p53 levels, some targets can be activated 
by basally expressed p53. p53 also may have a bona fide 
transcription-independent, mitochondria-associated role 
in inducing apoptosis (Moll et al., 2005; Schuler and Green, 
2005). It is possible that both transcription-dependent and 
transcription-independent functions of p53 are required for 
promoting apoptosis and limiting tumorigenesis. Indeed, 
PUMA, a proapoptotic protein encoded by a p53 target gene, 
is required to release cytoplasmic p53 from the antiapoptotic 
protein Bcl-XL to facilitate mitochondrial outer membrane 
permeabilization (Chipuk et al., 2005). Moreover, deletion of 
the p53 binding sites in the endogenous PUMA promoter 
in human colorectal cancer cells (by homologous recombi-
nation) reduces both PUMA expression and DNA damage-
induced apoptosis (Wang et al., 2007a). We discuss below 
recent developments in the understanding of transcriptional 
regulation by p53, focusing on but a few of the many notable 
reports that examine how p53 selects its target genes and the 
ensuing cellular outcome.
Thinking Globally
Elucidation of p53’s function as a transcriptional regulator 
will require the integration of both macroscopic and micro-
scopic views to evaluate the complete set of p53-regulated 
genes and to delve into the mechanisms by which it selects 
its target genes in different settings. From the macroscopic 
vantage point, it will be important to know the full repertoire 
of direct transcriptional targets bound and regulated by p53. 
One recent review lists 129 such p53 transcriptional targets 
that were identified as a result of either single gene discover-
ies or multigene screens (Riley et al., 2008). There are likely to 
be many more genes specifically bound and activated by p53. 
Furthermore, the number of genes whose expression is altered 
indirectly upon induction of p53 is likely to be in the thousands. 
To find new direct p53 targets, there is well-justified interest 
in the identification of sites within the human genome that are 
bound by p53. The original consensus site recognized by p53 
consisting of two copies of the sequence—RRRCA/TT/AGYYY 
(R, purine; Y, pyrimidine)—has been refined by using bioin-
formatics analysis (Hoh et al., 2002; Miled et al., 2005; Riley 
et al., 2008; Sbisa et al., 2007) and experimental approaches 
using chromatin immunoprecipitation (chIP) in conjunction with 
microarrays (“chIP on chip”) (Cawley et al., 2004; Hearnes et al., 
2005; Smeenk et al., 2008) or chIP-paired-end (PET) sequenc-
ing (Wei et al., 2006). Such screens for p53-binding sites have 
provided intriguing information regarding p53 target binding. 
First, they have revealed that not all “good” p53-binding sites 
in the genome are occupied by p53 under the conditions that 
were used. Factors such as the spacing between half sites (Jor-
dan et al., 2008), the location of a site within a heterochromatic 
locus, or the presence at the site of a p53 dominant-negative 
isoform or family member are all likely to be important determi-
nants of p53 association with any particular site. Second, not 
all regions bound by p53 have sequences that conform to the 
p53 consensus site. This could be the result of p53 association 
with other DNA-binding proteins such as nuclear transcription 
factor Y (NF-Y) (Imbriano et al., 2005). Third, not all genes in the 
vicinity of bound p53 are transcriptionally regulated as a result 
of p53 binding. Eukaryotic gene promoters usually require 
multiple factors for activation. Moreover, the presence of core-
pressors at the same promoter could counteract the activity of 
p53. It will be important to both refine and extend the current 
bioinformatic and experimental approaches to obtain a more 
dynamic global view of p53 binding and activation. Although 
daunting in terms of effort and cost, it will be crucial to eluci-
date the extent and kinetics of p53 binding at genomic targets 
after different stimuli and in different types of cells.
Surveys of genes whose expression is altered upon induction 
of p53 always include large numbers of genes whose expression 
is reduced. Indeed, transcriptional repression by p53 is impor-
tant in promoting cell death. p53 may reduce gene expression 
by several mechanisms (Laptenko and Prives, 2006). First, p53 
may increase the expression of a protein (such as p21) that pre-
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vents phosphorylation of the retinoblastoma protein, thereby 
maintaining genes regulated by the E2F transcription factors 
in a repressed state. Indeed, the repression of numerous p53 
target genes has been shown to be mediated by p21 (Lohr et 
al., 2003; Tang et al., 2004; Shats et al., 2004; Baptiste-Okoh et 
al., 2008b). Second, p53 transcriptional repression may result 
from the direct association of p53 with promoters that possess 
binding sites for other transcription factors such as Sp1 (Esteve 
et al., 2007; Innocente and Lee, 2005; Sengupta et al., 2005; 
Zaky et al., 2008; Zhan et al., 2005), NF-Y (Imbriano et al., 2005; 
Matsui et al., 2004), or SMADs (found in combination with a 
p53 recognition sequence) (Wilkinson et al., 2008). Promoters 
repressed by p53 may also harbor a cell cycle-dependent ele-
ment/cell cycle gene homology region (CDE/CHR element), a 
sequence recognized by several different transcription factors 
(Rother et al., 2007; St Clair et al., 2004). Third, gene repres-
sion could be mediated by unique p53 “repression” elements 
to which p53 binds directly (Godar et al., 2008; Johnson et al., 
2001).
Gene expression microarrays have revealed that p53 reg-
ulated genes are not limited to those involved in cell cycle 
arrest and apoptosis. Many other gene clusters associated 
with diverse processes such as DNA repair, transcription, cell 
adhesion, cell mobility, metabolism, and membrane functions 
are also affected by p53 activity. The complex repertoire of 
p53 regulated genes further highlights the imperative need to 
understand how p53 selects its targets.
Acting Locally
Moving from the macroscopic to the microscopic, much atten-
tion has been paid to the mechanisms by which p53 selects 
some of its key target genes. We will start by discussing a 
number of studies that have revealed new facets of how p53 
contacts its binding sites in DNA, some of which have also 
provided insights into p53-binding site selectivity in vitro and 
in cell culture. X-ray crystallographic analyses have revealed 
a new interface in a p53 dimer bound to DNA (Ho et al., 2006) 
and shown that four p53 core domains bind as a dimer of dim-
ers to two cognate half sites in DNA (Kitayner et al., 2006). 
Interestingly, there are DNA-sequence-specific differences in 
the contacts made between the p53 protein surfaces, which 
could translate into the degree of induction for a given target 
gene (Kitayner et al., 2006). Now that Fersht and colleagues 
(Tidow et al., 2007) have succeeded in obtaining a structure of 
full-length p53 bound to DNA by using a combination of small 
angle X-ray scattering and nuclear magnetic resonance, it will 
be possible to gain a clearer view of how p53 interacts with dif-
ferent DNA sequences.
How does p53 identify its cognate binding sites in a vast sea 
of genomic DNA? Although this question is still unanswered, 
two studies have shown that the p53 protein is capable of dif-
fusing two dimensionally on DNA in vitro (McKinney et al., 2004; 
Tafvizi et al., 2008). It is not yet known over what distances p53 
can slide on DNA, whether p53 can similarly diffuse along DNA 
that is wrapped around a histone octamer, and whether the 
chromatin state of the DNA regulates how p53 binds or slides. 
Experimental and molecular modeling studies have revealed 
that the propensity of a p53 cognate binding sequence to 
bend has a significant impact on the stability and affinity of 
p53 binding (Batta and Kundu, 2007; Pan and Nussinov, 2008). 
A fascinating albeit somewhat exotic study has revealed that a 
tethered photo-oxidant, anthraquinone, can actually transmit 
electrical charge through the DNA to p53 protein bound at a 
distance, resulting in the photo-oxidation and specific release 
of p53 from some cognate binding sites (for example, sites in 
the promoter of the gene encoding Mdm2) but not others (for 
example, sites in the p21 promoter) (Augustyn et al., 2007). 
These findings may relate to changes in the oxidative state of 
p53 after hydrogen peroxide treatment of cells and the ensuing 
selective impact on its ability to activate transcription.
Several proteins and small molecules have been shown to 
regulate the DNA-binding specificity of p53. Some of these 
work through the p53 tetramerization region. For example, a 
p53 isoform (p53β), that can form heterotetramers with wild-
type p53, stimulates wild-type p53 binding and activation of 
the Bax (Bcl-2-associated X protein) gene, but it does not pro-
mote p53 activation of p21 expression (Bourdon et al., 2005). 
The tyrosine kinase c-Abl, on the other hand, stabilizes p53 
tetramerization and augments the binding of p53 to the p21 
promoter instead of the Bax promoter (Wei et al., 2005a). Oth-
ers factors may affect p53 DNA binding by directly interacting 
with the central core domain of p53. Among the earliest dis-
covered and still studied of these proteins are the apoptosis 
stimulating proteins of p53 (ASPPs), which selectively stimulate 
p53 binding and activation of the Bax promoter but not the 
p21 promoter (Sullivan and Lu, 2007). In contrast, a zinc-finger 
protein called hematopoietic zinc finger (HZF), itself a p53 tran-
scriptional target, interacts with the p53-DNA-binding domain 
and promotes the recruitment of p53 to the p21 and 14-3-3 
promoters, but not to the Bax promoter or the promoter of the 
proapoptotic Noxa gene. These findings are consistent with 
the observation that mouse embryonic fibroblasts lacking HZF 
exhibit increased Bax expression and decreased p21 expres-
sion in comparison to that in wild-type mouse embryonic fibro-
blasts (Das et al., 2007). Even a small molecule such as nicotin-
amide adenine dinucleotide (NAD+) can selectively impact p53 
binding to DNA in vitro and correspondingly affect the level of 
p53-induced Mdm2 expression without impacting p21 expres-
sion in vivo (McLure et al., 2004). These are likely only a few of 
the ways in which p53 DNA binding and transcriptional activa-
tion can be differentially regulated.
Modifying the Regulator
Since the first discoveries revealing that p53 undergoes stress-
induced phosphorylation or acetylation, there have been 
numerous complicated studies describing these (and other) 
modifications to p53 and deciphering how they affect p53 
function as a transcriptional regulator. As there are a number 
of excellent reviews covering these aspects of p53 regulation 
(Appella and Anderson, 2001; Bode and Dong, 2004; Kruse 
and Gu, 2008; Olsson et al., 2007), we will focus on discussing 
findings relevant to a few key p53 modifications that selectively 
impact the cellular outcomes of p53 activation (Figure 4).
The Many Roles of Phosphorylation
Serine 46 (S46), an N-terminal phosphorylation site in 
human p53, clearly has discriminatory functions for p53 as 
a transcriptional activator. Phosphorylation at this residue is 
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correlated with an altered p53 transcriptional program that 
includes the induction of p53-regulated apoptosis-inducing 
protein 1 (p53AIP1), a proapoptotic factor that promotes the 
release of mitochondrial cytochrome c during apoptosis. 
One of the protein kinases that phosphorylate this site is 
homeodomain interacting protein kinase 2 (HIPK2) (D’Orazi 
et al., 2002; Hofmann et al., 2002), a protein regulated by the 
tumor suppressor Axin (Rui et al., 2004). Under conditions 
of moderate DNA damage, the p53 negative regulator Mdm2 
induces HIPK2 degradation (Figure 4). In contrast, severe 
DNA damage results in reduced Mdm2 levels, thus allowing 
the now stable HIPK2 to phosphorylate p53 at S46 to induce 
cell death (Rinaldo et al., 2007). These findings implicate 
Mdm2 as a determinant of alternative cell fates that are reg-
ulated by p53 (Shmueli and Oren, 2007), a concept that we 
will return to later in this Review. The observations also sup-
port the previously mentioned view that the extent of cellular 
damage may determine whether p53 acts as a survival factor 
or a death factor. To make matters more complicated, p53 
not only negatively regulates HIPK2 through inducing Mdm2 
expression for its degradation, but also positively regulates 
HIPK2 by facilitating its caspase-mediated cleavage and 
subsequent activation (Gresko et al., 2006). There are other 
protein kinases that can either directly phosphorylate S46 
or are otherwise required for S46 phosphorylation. These 
include dual-specificity tyrosine-phosphorylation-regulated 
kinase 2 (DYRK2) (Taira et al., 2007), AMPK (Okoshi et al., 
2008), protein kinase C delta (Yoshida et al., 2006), and p38 
mitogen-activated protein kinase (Perfettini et al., 2005). 
That several kinases can phosphorylate S46 both supports 
the importance of this site in p53 function and makes the 
understanding of its regulation more challenging. S58 in the 
mouse p53 protein is likely the corresponding residue of S46 
in the human protein (Cecchinelli et al., 2006), and it will be 
interesting to determine the physiological outcome of mutat-
ing this residue in mice.
C-terminal phosphorylation sites in p53 have also been 
linked to selective impacts on target gene expression and out-
comes. S315 is somewhat unique among these sites in that it 
is phosphorylated by growth-promoting kinases. Phosphory-
lation of S315 regulates the ability of p53 to repress Nanog, a 
factor required for stem cell self-renewal, through the recruit-
ment of the transcriptional regulator and corepressor mSin3A. 
Mice harboring mutant p53 where S315 is mutated to alanine 
(S315A) are impaired in Nanog repression. However, the inter-
pretation of experiments where S315 is disrupted is compli-
cated by the proximity of S315 to the major nuclear localization 
signal sequence of p53. The transcription factor E2F requires 
S315 to facilitate nuclear retention of human p53 (Fogal et al., 
2005), whereas the binding of this region by the glycogen syn-
thase kinase-β (GSK-β) after ER stress causes cytoplasmic 
retention and destabilization of p53 (Qu et al., 2004). Also within 
the C terminus of p53 are S366 and threonine 387 (T387), two 
sites that have been shown to be regulated by the checkpoint 
kinases Chk1 and Chk2. Downregulation of either Chk kinase 
or the mutation of these two p53 phosphorylation sites selec-
tively affects p53 activation, promoter binding, and acetylation 
of C-terminal lysines on p53 (Ou et al., 2005). In mice, substitu-
tion of S389, a UV-inducible modification, with alanine results 
in altered expression of some p53 target genes and generally 
reduced repression of p53 targets in UV irradiated cells (Bruins 
et al., 2007, 2008). Although there is still much to learn about 
how different phosphorylations regulate p53, several sites 
clearly have discriminatory impacts on some target genes in 
comparison to others.
The Ever-Shifting Functions of p53 Lysines
As complex as the consequences of p53 phosphorylation 
are, the roles of p53 lysine residues are even more perplex-
ing. Numerous studies have implicated the lysines within the 
extreme C terminus of p53 as being important for the protein’s 
transcriptional activities. Yet, confoundingly, two knockin mice 
in which either six (Feng et al., 2005) or all seven (Krummel et 
al., 2005) of the extreme C-terminal lysines were mutated to 
arginines have mild (albeit somewhat different) phenotypes. A 
possible explanation for this puzzling result comes from the 
identification of two acetylation sites within the p53 central core 
domain. The first of these two sites, lysine 120 (K120), is acety-
lated in vivo in response to DNA damage and increases PUMA 
but not Mdm2 expression. Two MYST family histone acetyl 
transfereases (HATs)—Tip60 (Tang et al., 2006) and hMOF 
(Sykes et al., 2006)—are capable of acetylating K120. Cells 
overexpressing a mutant form of p53 where K120 is mutated 
to arginine (K120R) show a partial defect in apoptosis. It should 
be noted that when the mutant K120A p53 protein is expressed 
at physiological levels, the defect in apoptosis is stronger than 
when the mutant protein is transiently overexpressed, indicat-
Figure 4. Selective Impact of p53 
 Modifications
p53 protein domains include the transcriptional 
activation domain I (TAD 1, residues 20–40), the 
transcriptional activation domain II (TAD II, resi-
dues 40–60), the proline domain (PP, residues 
60–90), the sequence-specific core DNA-binding 
domain (DNA-binding core, residues 100–300), the 
linker region (L, residues 301–324), the tetramer-
ization domain (Tet, residues 325–356), and the 
lysine-rich basic C-terminal domain (++, residues 
363–393). A few examples are depicted of resi-
dues that when modified by phosphorylation (P), 
acetylation (Ac), or ubiquitination (Ub), result in a 
specific cellular outcome in response to p53 ac-
tivation (for example, apoptosis versus cell cycle 
arrest) that depends on preferential activation of 
the indicated target genes.
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ing that abnormally high levels of p53 can produce misleading 
results (Zupnick and Prives, 2006). Furthermore, the loss of one 
copy of Tip60 in mice impairs the Myc-induced DNA-damage 
response without impacting the p53 transcriptional program, 
suggesting that reduced Tip60 levels may not impact p53 in 
vivo (Gorrini et al., 2007).
The second core domain acetylation site, K164, is modified 
by the transcriptional coactivators p300 and CREB-binding 
protein (CBP) and appears to be important for the activation 
of the majority of p53 target genes (Tang et al., 2008). When 
six of the extreme C-terminal lysines in p53 are mutated in 
addition to mutation of K120 and K164, the resulting p53 
mutant protein (p53 8KR) is virtually inert. This mutant protein 
lacks the transcriptional activation activity required to induce 
a plethora of its target genes, including those encoding p21, 
PUMA, Bax, and p53-inducible gene 3 (PIG3). The Mdm2 
promoter is the one notable exception: Mdm2 expression is 
induced by the 8KR p53 protein to a level similar to that seen 
with wild-type p53. What is unique about the Mdm2 promoter 
and its regulation by p53? In cultured human breast cancer 
MCF7 cells, an ATPase component of the SWI/SNF chromatin 
remodeling complex called Brg1 is required for p53 binding 
and induction of the p21 promoter but not the Mdm2 promoter 
(Xu et al., 2007). This suggests that, compared to other p53 
targets, the Mdm2 promoter may not be as tightly associated 
with nucleosomes. Whether this is relevant to the observation 
that unacetylatable p53 can still activate expression of Mdm2 
remains to be determined.
Findings implicating p300 and CBP as being critical for 
p53’s activities in both arrest and apoptosis are supported 
by the observation that the F box protein Skp2 prevents p300 
from binding to and acetylating p53 with consequent reduced 
expression of p53 targets such as p21 and Puma (Kitagawa et 
al., 2008). However, these data will need to be reconciled with 
the observation that the targeted deletion of p300 in human 
HCT116 colon cancer cells results in reduced p21 expression 
but increased Puma expression, with the corresponding cellu-
lar outcomes of reduced cell cycle arrest and increased apop-
tosis (Iyer et al., 2004).
K320 in p53 is a substrate of the transcription coactivator 
P300/CBP-associated factor (PCAF). It is another lysine that 
plays an interesting role in p53 target gene selection. Cells 
ectopically expressing a mutant p53 where K320 was mutated 
to glutamine (K320Q; Q is thought to mimic acetylation) dis-
play decreased apoptosis after some forms of DNA damage. 
Although the K320Q mutant protein is capable of inducing p21 
expression, it can neither induce the expression of the gene 
encoding apoptotic peptidase-activating factor 1 (APAF1) 
nor repress some p53 targets such as the gene encoding 
the apoptosis-inhibitor protein survivin (Knights et al., 2006). 
Acetylated K320 also preferentially activates two transcrip-
tional targets of p53 (Coronin 1b and Rab13) whose gene prod-
ucts associate with the cellular cytoskeleton and are involved 
in neurite outgrowth during axonal regeneration (Di Giovanni et 
al., 2006). Treatment of cultured cells with a hypoxia-mimicking 
drug (etoposide) leads to increased association of PCAF and 
K320-acetylated p53 with the p21 promoter compared to p53 
acetylated at K382, despite a global decrease in the amount 
of p53 acetylated at K320 (Xenaki et al., 2008). The possibil-
ity that, under some conditions, acetylation of K320 predis-
poses p53 to activate p21 and decreases its ability to induce 
proapoptotic targets genes is nicely consistent with the obser-
vation that K320R knockin mice harbor several cell types that 
display increased apoptosis and higher expression of relevant 
p53 target genes (Chao et al., 2006).
Of course, lysine mutations do not exclusively reflect the 
loss of p53 acetylation. Other lysine modifications such as 
methylation, ubiquitination, sumoylation, and neddylation have 
the potential to also alter p53’s transcriptional activity. Experi-
mental results obtained using lysine amino acid substitutions 
need to be viewed as only circumstantial and not definitive. A 
zinc-finger protein E4F1, first identified as a cellular target of 
the Adenoviral E1a protein, ubiquitinates p53 at K320. Interest-
ingly, ubiquitination at K320 does not destabilize p53. Rather, 
it selectively facilitates p53 activation of p21 and cyclin G1 
expression without affecting the expression of the proapop-
totic gene Noxa. This is consistent with the observation that 
E4F1 expression markedly reduces UV-dependent p53-medi-
ated cell death (Le Cam et al., 2006). Intriguingly, PCAF, which 
has been unequivocally shown to acetylate p53 at K320, has 
also been reported to exhibit E3 ubiquitin ligase activity toward 
Mdm2 (Linares et al., 2007). Future studies may reveal whether 
there is crosstalk between PCAF and E4F1 in the regulation of 
p53 and Mdm2.
Regarding alternate modifications of p53 lysines, methyla-
tion in particular has been a subject of great interest. Methyla-
tion of K372 by the SET domain methyltransferase Set9 leads 
to increased p21 expression (Chuikov et al., 2004), but whether 
this has a selective impact on p53 target gene activation has 
not been determined. Methylation of K382 by Set8, however, 
has the interesting effect of suppressing the activation of sev-
eral strong p53 targets but not others that are normally less 
well induced (Shi et al., 2007). K370 is methylated by the meth-
yltransferase Smyd2 (SET and MYND domain containing 2) 
and causes the repression of p53 transcriptional activation, 
although K370 methylation is itself inhibited by Set9 methy-
lation of K372 (Huang et al., 2006). The demethylase LSD1 
removes K370 dimethylation and in doing so prevents p53 
from interacting with p53-binding protein 1 (53BP1), a coacti-
vator of p53 (Huang et al., 2007). The functional roles of p53 
lysine modifications are further complicated by the crosstalk 
that exists between methylation and acetylation (Ivanov et al., 
2007). Specifically, methylation of K372 by Set7/9 is induced 
by DNA damage and correlates with increased acetylation of 
C-terminal p53 lysines including K382.
All told, a rather daunting set of combinatorial possibilities 
can result from p53 lysine modifications. It is anticipated that 
once a full set of data has accumulated regarding the possible 
combination of modifications, great computational power will 
be needed to deconstruct their impact on p53 functions and 
the cellular outcomes. In the meantime, new p53 modifica-
tions continue to be uncovered. It was recently reported that 
the protein arginine methyltransferase 5 (PRMT5) is involved in 
methylation of at least two arginine residues (R333 and R335) 
within the p53 tetramerization domain (Jansson et al., 2008). 
Depletion of PRMT5 by siRNA in human cancer cell lines leads 
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to increased apoptosis along with loss of p21 and a modest 
increase in proapoptotic Puma and Noxa proteins (Jansson et 
al., 2008). Whether other p53 arginines are methylated remains 
to be determined.
Changing Partners
Numerous noncovalent modifiers of p53 can also exert dis-
criminatory effects on its ability to activate or repress its gene 
targets (Figure 5). Indeed, as one might expect, there is com-
plex interplay between p53 modifications and its binding part-
ners. The best studied and validated of the p53 interactors are 
its negative regulators Mdm2 and MdmX. A wealth of studies 
have delved into their interactions with p53 and have been well 
reviewed (Marine et al., 2006, 2007; Poyurovsky and Prives, 
2006; Toledo and Wahl, 2006). Therefore, we will only highlight 
here a few recent findings in this aspect of the p53 field. Mech-
anistic understanding of how Mdm2 and MdmX repress p53 
transcriptional activity is an area still requiring insight. A recent 
study showing that the loss of p53 rescues the early lethality in 
mice caused by a mutant form of Mdm2 lacking E3 ligase activ-
ity indicates the primacy of the role of Mdm2 in degrading p53 
(Itahana et al., 2007). Nonetheless, Mdm2 has also been shown 
to reduce p53 acetylation by displacing p300 from p53 (Ito et al., 
2001; Kobet et al., 2000; Teufel et al., 2007), as well as by inhibit-
ing and degrading PCAF (Jin et al., 2004). Mdm2 can also recruit 
the histone deacetylases HDAC1 (Ito et al., 2002) and KAP1 
(Wang et al., 2005), thus providing additional means by which 
Mdm2 might function to repress acetylation of either p53 or his-
tones in the vicinity of p53-binding sites. Mdm2 expressed from 
its endogenous locus associates with p53 at the p21 promoter 
(Arva et al., 2005; Minsky and Oren, 2004; Ohkubo et al., 2006; 
Tang et al., 2008; White et al., 2006). Ectopically overexpressed 
Mdm2 (and MdmX) can bind to several other p53 target pro-
moters, with the exception of the Mdm2 promoter itself (Tang 
et al., 2008). Having about 2-fold higher levels of Mdm2 pro-
tein in H1299 cells with tetracycline-regulated p53 expression 
leads to lower levels of PIG3 and 14-3-3σ but does not affect 
p21 or Bax expression when compared to similar cells without 
extra Mdm2 (Ohkubo et al., 2006). Due to its ability to either dis-
place acetylases or directly ubiquitinate histone H2B (Minsky 
and Oren, 2004), or possibly through other mechanisms, Mdm2 
coassociation with p53 at its target gene promoters allows it to 
negatively regulate p53 transactivation in a selective manner. 
How and when MdmX negatively regulates p53 are questions 
being actively pursued (for example, see Wang et al., 2007b). 
Perhaps the most challenging aspect of this field of study is 
integrating the roles of Mdm2 and MdmX in the regulation of 
p53 turnover and localization with their respective impacts on 
p53 transcriptional activities.
Intrinsic to the p53 protein is its ability to select different 
target genes. Within its N terminus, p53 possesses transac-
tivation domains (TADs; TAD I within residues 20–40 and TAD 
II within residues 40–60) and a proline-rich domain (spanning 
residues 60–90) that can also regulate transcription, possibly 
in conjunction with TAD II (Harms and Chen, 2006). Loss of TAD 
I function, most frequently achieved by simultaneous mutation 
of leucine 22 (L22) and tryptophan 23 (W23) (p53L22Q/W23S), 
produces a mutant p53 protein that was originally thought 
to be virtually bereft of all transcriptional activity. Yet, recent 
studies have shown that this mutant p53 protein can activate a 
subset of p53 proapoptotic targets in mouse cells (Johnson et 
al., 2005) and in human cells (Jung et al., 2006; Baptiste-Okoh 
et al., 2008a). These findings reveal that additional regions 
in p53—TAD II, the proline-rich region, or both—possess the 
capacity to function autonomously in transcriptional activation. 
Although TAD I and TAD II may be able to act independently, 
they also work in concert to recruit specific components of the 
multisubunit transcriptional activator STAGA complex, namely 
GCN5, Taf9, and ADA2b, in order to activate target genes such 
as p21, Puma, and GADD45 (Gamper and Roeder, 2008). Fur-
thermore, the p53-mediated transcriptional repression that is 
induced by hypoxia requires both TAD I and TAD II (Hammond 
et al., 2006). Based on data from studies examining p53L22Q/
W23S, however, it is possible that some p53 targets do not 
require the STAGA complex. Other regions in the p53 protein 
with transactivation capability may be able to recruit distinct 
factors that are necessary to induce gene activation. Small 
molecules such as Nutlin (Vassilev et al., 2004) and compound 
1d (Ding et al., 2005), which bind to Mdm2 and disrupt the inter-
action between Mdm2 and TAD I of p53, can greatly increase 
p53 expression and activity (Ding et al., 2005; Vassilev et al., 
2004). Intriguingly, in contrast to the effect of Nutlin in inducing 
cell cycle arrest, another small molecule (RITA) that also binds 
to p53 and prevents it from interacting with Mdm2 causes 
apoptosis and downregulation of p21 expression in some cells 
(Enge et al., 2009). Whether these different compounds selec-
tively affect different p53 activation regions is a question of 
considerable interest.
Although intrinsic features of the p53 protein are critical to 
its ability to induce cell cycle arrest or cell death, an increas-
ing panoply of cellular factors have also been identified that 
Figure 5. p53-Interacting Proteins Exert 
Selective Influences on p53 Target Genes 
and Outcomes
Different proteins can bind to p53 to induce differ-
ent cellular outcomes to p53 activity. Proteins that 
interact with the p53 DNA-binding core (green), 
tetramerization domain (Tet, blue), or C-terminal 
basic domain (++, purple) are shown. Brn3A, Hzf, 
c-Abl, YB1, and p18/Hamlet selectively induce 
p53 activation of genes encoding cell cycle regu-
lators such as p21 to facilitate cell cycle arrest. In 
contrast, ASPPs, the zebrafish p53 variant del-
ta113p53, the p53 isoform p53β, Brn3b, NFκB/
p52, and Muc1 selectively activate the expression 
of apoptotic regulators such as PUMA, Bax, and 
Noxa to promote cell death.
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work with p53 to produce a specific cellular response (Figure 
5). Not surprisingly, there is an intimate relationship between 
the ability of p53 to activate its target genes and the transcrip-
tion machinery with which p53 interacts. It has been shown in 
recent years that the arginine methyl transferases CARM1 and 
PRMT1 collaborate with p300 to facilitate p53-mediated tran-
scription from DNA assembled into chromatin in vitro (An et al., 
2004). Additionally, components of a subcomplex (including the 
protein MED/TRAP220) of the mediator transcriptional coacti-
vator complex can interact with p53 (Zhang et al., 2005).
A multitude of p53 binding proteins that can redirect p53 
toward a specific cellular outcome have also been uncovered. 
For example, a well-studied p53 polymorphism at codon 
72—where the residue can be either proline (P72) or arginine 
(R72)—results in differential cellular outputs depending on the 
p53 variant: the R72 variant protein is more proapoptotic than 
the P72 allele (Pietsch et al., 2006). The ASPP family member, 
iASPP, preferentially binds to the P72 variant of p53 and inhib-
its its activity, providing a mechanistic explanation for why the 
R72 variant protein is more effective at inducing apoptosis 
than the P72 variant protein (Bergamaschi et al., 2006). As 
one example of the interplay between p53 modification and 
its interaction with regulatory factors, the peptidyl-prolyl cis/
trans isomerase Pin1 recognizes p53 phosphorylated at S46, 
leading to dissociation of iASPP from p53 and thereby pro-
moting apoptosis (Mantovani et al., 2007). Another example 
of a protein that binds to p53 and directs differential cellular 
outcomes is the p38-regulated protein p18/Hamlet. p18/Ham-
let associates with p53 and increases both p53-mediated 
apoptosis and activation of some p53 target gene promoters 
(e.g., Noxa) but not others (Puma, Bax, and p21) (Cuadrado 
et al., 2007). Intriguingly, cyclin G, itself a p53 target, may 
decrease levels of p18/Hamlet, providing another level of reg-
ulation of p53 outcomes (Cuadrado et al., 2007). Another pro-
tein, Brn3A, binds to p53 and specifically inhibits its ability to 
activate the Bax and Noxa promoters to promote apoptosis. 
However, Bm3A also cooperates with p53 to activate gene 
expression from the p21 promoter (Hudson et al., 2005). It 
remains to be seen if there is any direct competition or cross-
regulation between the activities exerted by p18/Hamlet and 
Brn3A. Interestingly, Brn3b, a related factor to Brn3A, func-
tions in the opposite manner as Brn3A by assisting p53 to 
activate Bax expression and not p21 expression (Budhram-
Mahadeo et al., 2006).
An interesting regulator of p53 targets genes is the p52 
subunit of the transcription factor NFκB, which inhibits p21 
expression but cooperates with p53 to increase Puma, DR5, 
and Gadd45 expression; p52 also directly associates with the 
promoters of these genes (Schumm et al., 2006). In the case of 
Muc1, however, an integral membrane glycoprotein that is fre-
quently overexpressed in cancer, it has been found that Muc1 
associates with the p21 promoter in a p53-dependent manner 
to facilitate p21 transcription. Interestingly, Muc1 also associ-
ates with the Bax promoter independent of p53 to repress Bax 
expression. Consistent with Muc1’s regulatory functions, the 
amount of Muc1 protein in cells shows positive correlations 
with cell cycle arrest and cell survival, and negative correla-
tions with cell death (Wei et al., 2005b). The Y-box-binding pro-
tein YB1 has a similar impact on p53. YB1 associates with p53, 
blocking its activation of Bax expression, but does not impede 
p53 induction of p21 expression (Homer et al., 2005). Finally, in 
zebrafish, another selective p53 regulator, itself a p53 variant 
(delta113p53), represses full-length p53 activation of arrest but 
not apoptosis genes (Chen et al., 2005).
In addition to myriad p53-binding proteins, several new pro-
teins have been identified that can also bind and regulate p53 
but have yet to be shown to impart any selectivity to p53 target 
gene activation. Among these proteins are Sug1, a compo-
nent of the 19S proteasome (Zhu et al., 2007), heterogeneous 
ribonucleoprotein particle K (hnRNPK), which possibly acts 
through Mdm2 (Moumen et al., 2005), Hbo1 (Iizuka et al., 2008), 
KLF5 (Zhu et al., 2006), NF-Y (Imbriano et al., 2005), clathrin 
heavy chain (Enari et al., 2006), and the orphan receptor TR3 
(Zhao et al., 2006). We will be very curious to learn whether 
any of these proteins exert promoter-selective effects on p53’s 
transactivation capabilities.
Finally, not all proteins that affect p53 transcriptional activi-
ties and outcomes interact directly with p53. Notable exam-
ples of this include a somewhat mysterious regulator of p53, 
a noncoding RNA expressed from the MEG3 gene locus. This 
noncoding RNA seems to selectively affect p53 in human cells 
by downregulating Mdm2 expression, increasing p53 expres-
sion, and stimulating p53 activation of at least one target gene 
(growth differentiation factor 15; GDF15), all without affect-
ing p21 transcription (Zhou et al., 2007). Another instance of 
these indirect p53 regulators is the transcriptional repressor 
Zbt4, which forms a heterotrimeric complex with the Sin3 core-
pressor and the transcription factor Miz1 in order to repress 
p53-mediated p21 induction and cell cycle arrest (Weber et al., 
2008). The transcription repressor Slug is a beautiful case in 
point of a factor that profoundly affects p53 outcomes without 
directly interacting with p53. The gene encoding Slug is a p53 
target, and Slug proteins bind to the p53-inducible Puma pro-
moter to repress both gene expression and irradiation-induced 
apoptosis in hematopoietic cells (Wu et al., 2005).
Yet another factor that binds to a subset of p53 target genes 
independently of p53 (for example, PIG3 and AIP1 but not p21 
or Puma) is the nuclear transport factor hCas/Cse1L that coop-
erates with p53 to activate only those genes to which it binds. 
At those promoters, hCas/Cse1L most likely functions by facili-
tating downregulation of the repressive histone trimethylation 
mark, K27 of histone H3 (Tanaka et al., 2007).
All told, numerous transcriptional mechanisms that direct 
p53 toward its different cellular outcomes have been reported. 
The levels of p53, its modifications, the proteins that directly 
interact with it, and the proteins that interact independent of 
p53 with its target promoters can all differentially affect the 
outcome of p53 activation (Figure 6).
New Kids on the Block: p53 and MicroRNAs
Protein-encoding genes are not the only transcription targets 
of p53. No less than seven groups independently reported in 
2007 that p53 can directly regulate the expression of select 
microRNAs (miRNAs), most dramatically the miR-34 locus 
consisting of miR-34a, miR-34b, and miR-34c (Bommer et al., 
2007; Chang et al., 2007; Corney et al., 2007; He et al., 2007; 
Raver-Shapira et al., 2007; Tarasov et al., 2007; Tazawa et al., 
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2007). Several reports showed that p53 
can bind directly to response elements 
within the miR-34a and miR-34b/c pro-
moters to stimulate transcription from 
this locus. Certainly, miR-34a expres-
sion is physiologically relevant to the 
impact of p53 activity on cells: it can 
induce cell cycle arrest and senescence, 
as well as facilitate cell death. Functional 
ablation of miR-34a reduces these p53-
mediated effects on cells. Notably, the 
miR-34 family is conserved in flies and 
worms, a rather infrequent occurrence 
among miRNAs. As is often the case with 
miRNAs, the most obvious challenge 
is to find the target genes of miR-34 
whose downregulation is required for 
cell-cycle arrest or cell death. Convinc-
ing candidates identified in some of the 
reports include the cell cycle regulators 
cyclin-dependent kinase 4 (CDK4) and 
cyclin E2, as well as the proto-oncogene 
mesenchymal-epithelial transition factor 
(Met) and the antiapoptotic factor Bcl2. 
More recently, the sirtuin SIRT1 was 
also shown to be a target of miR-34a, 
and its downregulation correlates with 
increased acetylation of p53 (Yamakuchi 
et al., 2008). The discovery of miR-34a 
as a key p53 target begs the question 
of whether its levels are altered in can-
cer. Satisfyingly, some of the aforemen-
tioned studies uncovering p53 regula-
tion of the miRNA locus report markedly 
lower amounts of miR-34 in some human 
tumors and tumor-derived cell lines 
(Bommer et al., 2007; Chang et al., 2007; 
Tazawa et al., 2007).
miR-34 is not the only microRNA to 
be targeted by p53. Several of the first 
publications identifying the miR-34 
locus also found other possible miRNA 
targets of p53. It has now been reported 
that miR-192 and miR-215 are induced 
by p53 and promote increased p21 
expression (Braun et al., 2008). Moreover, miR-145 has been 
implicated as a p53 target that can repress c-myc expression 
(Sachdeva et al., 2009). In fact, a number of miRNAs that tar-
get antiproliferative genes have been shown to be repressed 
by p53 in a manner that requires E2F, not unlike other tar-
gets of p53-mediated repression (Brosh et al., 2008). Note 
that although the small molecule Nutlin can induce miR-34a 
expression and senescence in some cells such as normal 
human fibroblasts (Kumamoto et al., 2008), it fails to induce 
miR-34a and p21 expression in at least one tumor cell line 
(BV173 leukemia cells) that instead undergoes apoptosis upon 
Nutlin treatment (Paris et al., 2008). Thus, like other p53 target 
genes, miR-34a is not universally induced upon the activation 
of p53. It will be interesting for future 
studies to delve into the mechanism of 
its discriminatory regulation.
Therapeutic Applications of p53
Although there is still much to learn, 
it seems clear that manipulating the 
p53 pathway will bring considerable 
therapeutic benefits. As p53 activity is 
impaired or defective in most human 
cancers, regardless of type or tissue of 
origin, one obvious goal is to try and re-
establish the growth-inhibitory functions 
of p53 in cancer cells. This approach 
is elegantly supported by animal stud-
ies where reactivation of wild-type p53 
leads to efficient tumor regression (Mar-
tins et al., 2006; Ventura et al., 2007; Xue 
et al., 2007). So how might p53 be reac-
tivated? One line of attack that has been 
successful in the clinic is the use of gene 
therapy to reintroduce p53 into tumor 
cells by means of vectors such as aden-
oviruses (Senzer and Nemunaitis, 2009). 
Our growing understanding of how p53 
is regulated has also led to the devel-
opment of small molecule drugs that 
stabilize and activate the p53 protein. 
Although these drugs mostly function by 
interfering with the ability of Mdm2 to tar-
get p53 for degradation, cell-based drug 
screens have also identified inhibitors 
of sirtuins—protein deacetylases that 
can restrain p53 activity—as effective 
p53-activating agents (Lain et al., 2008). 
These types of drugs, some of which are 
in advanced stages of preclinical devel-
opment or early clinical trials (Shangary 
and Wang, 2009), are predicted to show 
efficacy in tumors that retain wild-type 
p53. It is worth noting that the develop-
ment of such drugs has sparked a vigor-
ous debate about the potential toxicity 
that a systemic activation of p53 may 
cause in normal tissues. In animal mod-
els, the absence of Mdm2 in normal p53-expressing tissues is 
alarmingly detrimental (Ringshausen et al., 2006), although it 
might be hoped that Mdm2-inhibiting drugs will be less effec-
tive, and so easier to tolerate, than ablation of the Mdm2 gene. 
Furthermore, because these drugs are not genotoxic, they will 
hopefully avoid some of the damage inflicted by conventional 
chemotherapies, which of course also activate p53 in all cells. 
Intriguingly, some studies have suggested that Mdm2-inhibiting 
drugs function much better in cells undergoing DNA-damage 
signaling, a characteristic that might further distinguish nor-
mal cells from cancer cells (Brummelkamp et al., 2006). If the 
use of p53 activators in cancer therapy proves to be incred-
ibly successful, we may need to consider the possible proag-
Figure 6. Multiple Mechanisms of 
 Differential p53 Target Gene Regulation
The cellular response to p53 activation can be 
determined by differential target gene activation. 
Whether a given promoter is activated or re-
pressed depends on the amount of p53 protein, 
its modification state, and the cofactors present 
at the promoter. p53 protein levels or modification 
state can also dictate which genes are targeted 
for transcriptional activation. The induction or re-
pression of p53 target gene transcription can also 
depend on the presence of numerous coactivators 
or additional cooperating factors that enhance or 
repress p53-induced transcription.
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ing effects of p53 activation during systemic long-term treat-
ment with these drugs, although at present such concerns will 
likely seem trivial to most cancer patients. Restoration of p53 
function in those cancers expressing mutant p53 is even more 
challenging, although small molecules that refold some mutant 
p53 proteins and thus reactivate their wild-type functions have 
been described (Selivanova and Wiman, 2007). This approach 
is technically difficult, but it may be an excellent way to selec-
tively target cancer cells that express mutant p53 proteins.
The concept that we should be trying to reactivate p53 in cancer 
cells is supported by experimental data and many human stud-
ies that show a correlation between mutations in p53 and poor 
disease prognosis (Petitjean et al., 2007). However, as we have 
highlighted in this Review, the cellular response to p53 can range 
widely from cell death to cell survival, and the consequences of 
retaining p53 activity in tumor cells are similarly difficult to pre-
dict. Indeed, the retention of wild-type p53 has been shown to 
protect breast cancers from some forms of cytotoxic chemo-
therapy and so can be associated with a poor response to treat-
ment (Bertheau et al., 2008). Possibly this effect of wild-type p53 
could be exploited for therapeutic benefit. In this approach, failure 
of tumor cells to mount a p53-mediated response would make 
them particularly sensitive to cytotoxic drugs that function dur-
ing S phase or the G2/M phase transition of the cell cycle. These 
drugs would be much less toxic to normal cells that can benefit 
from p53’s cell cycle arrest and survival activities (Sur et al., 2009). 
An extension of this idea is to use drugs that activate p53 to fur-
ther protect normal cells or tissue during the treatment of can-
cers harboring mutant p53 alleles (Carvajal et al., 2005; Kranz and 
Dobbelstein, 2006). Somewhat confusingly, the same concept of 
chemoprotection of normal tissue has also been proposed for 
the use of p53 inhibitors. It is clear that much of the toxicity seen 
in response to conventional genotoxic chemotherapies is due to 
the activation of p53 and the subsequent p53-induced death of 
radiosensitive cells in the hematopoetic system, gut lining, and 
other tissues. In this case, inhibition of p53 in normal cells may 
protect them from death, thereby increasing the patient’s toler-
ance to higher and hopefully more effective doses of radiation or 
chemotherapy (Gudkov and Komarova, 2005; Strom et al., 2006). 
Mouse studies support this strategy, suggesting that many side 
effects of acute genotoxic insult might be avoided by a short-term 
inhibition of p53, without causing a substantial loss in tumor sup-
pressor activity (Christophorou et al., 2006).
The potential use of p53 in therapy is not limited to cancer. 
For some disorders, the inhibition of p53 (or at least the inhi-
bition of the p53-mediated apoptotic response) could be a 
desired therapeutic goal. This area of p53-directed therapy is 
still underexplored, but p53-inhibitory compounds have been 
used with some success in animal models of ischemia and 
Parkinson’s disease (Duan et al., 2002; Leker et al., 2004).
As drugs are developed that can reactivate wild-type func-
tions of mutant p53, or turn wild-type p53 on or off, our under-
standing of how best to use these new tools in therapy will 
grow. However, as we learn more about the intricacies of p53 
regulation and function, predicting the outcomes of these drug 
treatments becomes more difficult. The response of cancer 
cells to p53 is clearly complicated enough, but how modulating 
p53 might contribute to other aspects of disease and longevity 
is only just beginning to be explored. Perhaps in a few years, a 
similar review will be able to integrate the complexity of p53 into 
a clearer picture to give insights into how this knowledge may 
be used to improve the prognosis of not only cancer patients 
but sufferers of other diseases as well.
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